A 28-Day Rat THC Study Found Cardiovascular Tolerance Without Movement Tolerance
A 1976 rat study found tolerance to selected cardiovascular responses after repeated THC, while movement suppression persisted through twenty-eight days. Even within the cardiovascular measurements, pressor and depressor responses differed.
The repeated regimen affected endpoints differently
Daily injected THC produced adaptation in body-weight and temperature effects within the earlier treatment period. Spontaneous motor suppression did not become tolerant over the full regimen. A single tolerance label would therefore conceal a persistent behavioral effect.
The acute challenge contained multiple cardiovascular phases
In anesthetized controls, intravenous THC produced a transient pressure rise followed by sustained pressure lowering and cardiac slowing. Prior THC exposure reduced the later hypotensive and slowing responses but not the initial pressor response. The phase being measured changed the answer.
A noradrenaline control narrowed interpretation
Pressor responses to intravenous noradrenaline did not differ between treatment histories. This argued against a general alteration of every measured pressor response as the explanation. It did not identify one complete mechanism for the selective THC adaptation.
The study contributes an extended regimen with a persistent movement finding and phase-specific cardiovascular tolerance. It cannot establish human cardiovascular safety or show that a normalized pulse implies intact motor function. Anesthesia, challenge route and endpoint remain necessary qualifications.
Related: interpreting cannabis tolerance claims.
Research cited
Adams MD; Chait LD; Earnhardt JT. Tolerance to the cardiovascular effects of delta9-tetrahydrocannabinol in the rat. British journal of pharmacology (1976). doi:10.1111/j.1476-5381.1976.tb06957.x. Findings discussed from the study abstract.
